Citation APA
Brandão, M., Prisciandaro, E., Xenophontos, E., Mariolo, A., Sadeghi, A. H., Filippi, A. R., Levy, A., Bandura, A., Caramella, C., Dickhoff, C., de Margerie-Mellon, C., Faivre-Finn, C., Portik, D., Sanchez-Lorente, D., Ruysscher, D. D., Smit, E., Gobbini, E., Fadel, E., Ruffini, E., Olmetto, E., Cortiula, F., Bahce, I., Houda, I., Opitz, I., Naidoo, J., Edwards, J., Remon, J., Benitez, J. C., Trujillo, J. C., Derks, J., Amrane, K., Hartemink, K., Stathopoulos, K., Hendriks, L. E., Iglesias, M., Occhipinti, M., Guckenberger, M., Levra, N. G., Girard, N., Reguart, N., Mercier, O., Bironzo, P., Hofman, P., Petersen, R. H., Angelis, R. D., Abgral, R., Terrisse, S., Popat, S., Pierret, T., Blum, T. G., Ricardi, U., Dionisi, V., Berghmans, T., & Dingemans, A.-M. C. (2025). Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group. Lung cancer, 108798. doi:10.1016/j.lungcan.2025.108798
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/395465